Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. (ATRC) delivers pioneering medical technologies for cardiac arrhythmia treatment and minimally invasive surgical solutions. This dedicated news hub provides investors and healthcare professionals with essential updates on corporate developments, clinical advancements, and regulatory milestones.
Access timely information on FDA-cleared devices, atrial fibrillation treatment innovations, and strategic partnerships. Our curated collection includes earnings reports, product launch announcements, and peer-reviewed study results directly impacting cardiac care practices.
Key updates cover ablation system enhancements, left atrial appendage management solutions, and operational expansions. Bookmark this page for structured access to AtriCure's latest advancements in electrophysiology and cardiothoracic surgical technologies.
AtriCure, Inc. (NASDAQ: ATRC), known for its innovative therapies for atrial fibrillation (Afib) and related conditions, announced an upcoming investor education webcast in collaboration with Canaccord Genuity, focusing on Cryo Nerve Block Therapy. This event is scheduled for May 16, 2023, at 12:30 PM Eastern Time, featuring a Q&A session with management and a key opinion leader.
Additionally, AtriCure will present at the 2023 Bank of America Health Care Conference on May 10, 2023, at 11:00 AM Eastern Time. Both events aim to enhance investor understanding of AtriCure's cutting-edge technologies, including the Isolator® Synergy™ Ablation System, which is FDA-approved for persistent Afib treatment.
Interested participants can access live and archived webcasts through the Investors section of AtriCure's website.
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), announced its first quarter 2023 financial results will be released on May 2, 2023. The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. Interested participants can register here. AtriCure focuses on innovative technologies for Afib treatment, with products like the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, addressing a condition affecting over 37 million people worldwide.
AtriCure, a leader in innovative surgical treatments for atrial fibrillation (Afib), announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. The company’s management will conduct a fireside chat on April 17, 2023, at 1:30 PM EST. Interested parties can access a live audio webcast in the ‘Investors’ section on AtriCure's website. AtriCure focuses on the development of technologies for Afib treatment and LAA management, with over 37 million individuals affected by Afib globally. The firm’s devices, including the Isolator® Synergy™ Ablation System and the AtriClip® LAA Exclusion System, are widely used by healthcare professionals.
AtriCure, Inc. (Nasdaq: ATRC) reported a 20.4% increase in worldwide revenue for 2022, totaling $330.4 million. U.S. revenue reached $277.2 million, up 21.0%, while international sales rose 17.7% to $53.2 million. The fourth quarter revenue was $88.0 million, marking a 20.2% increase year-over-year. Despite strong growth, the company reported a loss from operations of $42.7 million for 2022, alongside a net loss per share of $1.02. Looking ahead, 2023 revenue is projected between $380 million and $387 million, reflecting growth of 15% to 17%. The company aims for adjusted EBITDA to break even in 2023.
FAQ
What is the current stock price of Atricure (ATRC)?
What is the market cap of Atricure (ATRC)?
